Managed Care


Bivalirudin, Cangrelor, and Stent Thombosis: New Trials Raise More Questions

C. Michael Gibson, MS, MD, of Harvard Medical School, discusses important aspects of the HORIZONS-AMI and EUROMAX trials and tackles the question of whether a longer infusion of bivalirudin could lead to a reduced risk of stent thrombosis within 24 hours.


4th Partnering With ACOs Summit Los Angeles, CA October 27–28, 2014
PCMH & Shared Savings ACO Leadership Summit Nashville, TN November 3–4, 2014
2014 Annual HEDIS® and Star Ratings Symposium Nashville, TN November 3–4, 2014
Medicare Risk Adjustment, Revenue Management, & Star Ratings Fort Lauderdale, FL November 12–14, 2014
World Orphan Drug Congress Europe 2014 Brussels, Belgium November 12–14, 2014
Healthcare Chief Medical Officer Forum Alexandria, VA November 13–14, 2014
Home Care Leadership Summit Atlanta, GA November 17–18, 2014
HealthIMPACT Southeast Tampa, FL January 23, 2015